Home  >>  About ROXRO  >>  Overview  >> Milestones

Milestones

Among our Recent Accomplishments, We Have:

Received FDA approval for SPRIX™ (ketorolac tromethamine).

FDA accepted our NDA for SPRIX for full review.

Completed a Series B financing that raised $42.7 million.

Completed a Phase 2 clinical study of ROX-828 for the treatment of migraine.

Our Near Term Goals Include:

Identify a US commercial partner for SPRIX.